Posted on February 8, 20212/8/21
G-BA Proposes RWE Scheme for Zolgensma Use in Germany
Posted on January 22, 20211/22/21
Italy Reimburses Novartis’ Luxturna for Hereditary Retinal Disease
Posted on June 3, 20206/3/20
FDA Sets September Review Date for Novartis’ Multiple Sclerosis Targeted B-Cell Therapy, Ofatumumab
Posted on May 18, 20205/18/20
Deciphera’s Qinlock Approved for Fourth-Line GIST Treatment by FDA
Posted on May 13, 20205/13/20
Zolgensma Proposed to Cost 167 Million Yen in Japan
Posted on April 23, 20204/23/20